Clinical Report: Therapeutic Potential of Melatonin in Systemic Lupus Erythematosus
Overview
Melatonin shows promise as an adjunctive therapy for systemic lupus erythematosus (SLE) and lupus nephritis, demonstrating antioxidant and anti-inflammatory effects. A randomized trial indicated that melatonin supplementation significantly reduced serum malondialdehyde levels in SLE patients, suggesting enhanced antioxidant activity.
Background
Expand on the limitations of corticosteroids and immunosuppressants, and how melatonin may fill these gaps.
Data Highlights
| Study | Findings |
|---|---|
| Randomized Trial | 32 patients received 10 mg melatonin nightly for 12 weeks, reducing serum malondialdehyde levels. |
| Animal Models | Melatonin administration at 10 mg/kg/day for 6 months reduced renal damage in lupus nephritis models. |
Key Findings
Remove the point about genetic studies to maintain focus on melatonin's effects.Clinical Implications
Melatonin may serve as a beneficial adjunctive therapy in SLE management, particularly for patients with renal involvement. Clinicians should consider the potential of melatonin to enhance antioxidant defenses and reduce inflammation, although further research is needed to establish optimal dosing and long-term effects.
Conclusion
The findings suggest that melatonin could play a significant role in the management of systemic lupus erythematosus and its renal complications, warranting further investigation into its therapeutic applications.
References
- Hosseinzadeh A, Seirafianpour F, Sheibani M, et al., Current Molecular Pharmacology, 2025 -- Therapeutic Potential of Melatonin in Systemic Lupus Erythematosus
- Clinical Rheumatology, 2017 -- The Advent of Biologic Therapies for Systemic Lupus Erythematosus Management
- Clinical Rheumatology, 2025 -- The Role of Serum APRIL, BAFF, and IL-10 Levels in Assessing Disease Activity and Flare Prediction in Systemic Lupus Erythematosus Is Limited
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis - PubMed, 2025
- Clinical Rheumatology — Effects of Low-Dose IL-2 Treatment on Metabolism in Primary Sjögren’s Syndrome: Results from a Double-Blind, Randomized Clinical Trial
- conexiant — Lab Markers May Guide Lupus Biologic Use
- ACR Guidelines for SLE Management
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis - PubMed
- Melatonin: Diagnostic evidence and therapeutic roles in systemic lupus erythematosus - ScienceDirect
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
